Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • ORBITA-2
Focal vs. Diffuse Coronary Artery Disease: How Disease Pattern Influences PCI’s Placebo-Controlled Symptom Relief in ORBITA-2
Posted inCardiology news

Focal vs. Diffuse Coronary Artery Disease: How Disease Pattern Influences PCI’s Placebo-Controlled Symptom Relief in ORBITA-2

Posted by MedXY By MedXY 04/22/2026
ORBITA-2 reveals PCI’s superior placebo-controlled angina relief in focal vs. diffuse coronary artery disease, with physiological disease patterns guiding treatment decisions.
Read More
  • Right Ventricular to Pulmonary Artery Coupling: A New Prognostic Marker in Heart Failure Therapy
  • Biventricular Pacing Outperforms Conduction System Pacing in Heart Failure: Key Insights from PhysioSync-HF Trial
  • Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients
  • Focal vs. Diffuse Coronary Artery Disease: How Disease Pattern Influences PCI’s Placebo-Controlled Symptom Relief in ORBITA-2
  • Unraveling the Gut-Heart Connection: How Leaky Gut Fuels Atrial Fibrillation in Aging
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in